Alterations of O-GlcNAc cycling enzymes OGT and OGA, as well as an elevated level of O-GlcNAcylation, have been observed in various solid cancers, including breast, colon, pancreas, liver and lung.18,30–32 We previously demonstrated that hyper-O-GlcNAcylation renders NSCLC cells to acquired cisplatin resistance via the regulation of p53 and c-Myc.21 We herein extend the knowledge that O-GlcNAcylation also regulates NSCLC cell motility, as shown by a decrease in cell motility upon OGT knockdown, which in turn reduces O-GlcNAcylation (Fig. 3e, f). The gene discussed is OGA; the disease is non-small cell lung carcinoma.